Evaluation of the Effects of mRNA-COVID 19 Vaccines on Corneal Endothelium.

IF 1.2 4区医学 Q3 OPHTHALMOLOGY

Ophthalmic epidemiology Pub Date : 2025-07-14 DOI:10.1080/09286586.2025.2522724

Fatma Sumer, Sevgi Subasi

{"title":"Evaluation of the Effects of mRNA-COVID 19 Vaccines on Corneal Endothelium.","authors":"Fatma Sumer, Sevgi Subasi","doi":"10.1080/09286586.2025.2522724","DOIUrl":null,"url":null,"abstract":"Purpose: The study aimed to compare corneal topographic and specular microscopic parameters before and after vaccination with activated (Pfizer -BioNTech (BNT162b2)) SARS-CoV-2 mRNA vaccine.Methods: 128 eyes of 64 patients were evaluated in this prospective study. The time interval between pre and post-vaccination examinations was nearly two and a half months (75.6 ± 4.5 days).The topographic evaluation was made with Sirius corneal topography (Sirius, CSO Inc, Florence, Italy) and specular microscopy was made with Tomey EM-4000 specular microscopy (Tomey GmbH, Japan). All patients underwent detailed ophthalmologic examination including best-corrected visual acuity assessment (BCVA), measurement of intraocular pressure (IOP), anterior segment evaluation with biomicroscopy, and dilated fundus examination.Results: The significant change in the topographic evaluation was the post-vaccine (542.0 (534.25-548.0)) increase in central corneal thickness compared to pre-vaccine values (528.0 (520.25-537.75) (p = 0.001). The endothelial cell density (ECD) was 2597 (2550.0-2646.50) before vaccination and 2378.0 (2299.0-2419.0) at least two months after vaccination (p < 0.001). The median mean coefficient of variation (CV) value was 39.0(38.0-42.0) before vaccination measurements and 42 (40-44) after vaccination measurements (p < 0.001). The mean hexagonality was 50.0 (48.25-52.0) before vaccination and 48(46-49) after vaccination (p < 0.001).The median central corneal thickness (CCT) value was 533(526-538) before vaccination and 548 (543.50-556) after vaccination (p < 0.001).Conclusion: Changes in corneal endothelium occur in the short term after two-doses of the Pfizer-BioNTech (BNT162b2) COVID-19 mRNA vaccine. Hence the endothelium should be closely monitored in those with a low endothelial count or who have had a corneal graft.","PeriodicalId":19607,"journal":{"name":"Ophthalmic epidemiology","volume":" ","pages":"1-8"},"PeriodicalIF":1.2000,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmic epidemiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/09286586.2025.2522724","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: The study aimed to compare corneal topographic and specular microscopic parameters before and after vaccination with activated (Pfizer -BioNTech (BNT162b2)) SARS-CoV-2 mRNA vaccine.

Methods: 128 eyes of 64 patients were evaluated in this prospective study. The time interval between pre and post-vaccination examinations was nearly two and a half months (75.6 ± 4.5 days).The topographic evaluation was made with Sirius corneal topography (Sirius, CSO Inc, Florence, Italy) and specular microscopy was made with Tomey EM-4000 specular microscopy (Tomey GmbH, Japan). All patients underwent detailed ophthalmologic examination including best-corrected visual acuity assessment (BCVA), measurement of intraocular pressure (IOP), anterior segment evaluation with biomicroscopy, and dilated fundus examination.

Results: The significant change in the topographic evaluation was the post-vaccine (542.0 (534.25-548.0)) increase in central corneal thickness compared to pre-vaccine values (528.0 (520.25-537.75) (p = 0.001). The endothelial cell density (ECD) was 2597 (2550.0-2646.50) before vaccination and 2378.0 (2299.0-2419.0) at least two months after vaccination (p < 0.001). The median mean coefficient of variation (CV) value was 39.0(38.0-42.0) before vaccination measurements and 42 (40-44) after vaccination measurements (p < 0.001). The mean hexagonality was 50.0 (48.25-52.0) before vaccination and 48(46-49) after vaccination (p < 0.001).The median central corneal thickness (CCT) value was 533(526-538) before vaccination and 548 (543.50-556) after vaccination (p < 0.001).

Conclusion: Changes in corneal endothelium occur in the short term after two-doses of the Pfizer-BioNTech (BNT162b2) COVID-19 mRNA vaccine. Hence the endothelium should be closely monitored in those with a low endothelial count or who have had a corneal graft.

查看原文本刊更多论文

mRNA-COVID - 19疫苗对角膜内皮细胞影响的评价

目的：比较（Pfizer -BioNTech (BNT162b2)）激活的SARS-CoV-2 mRNA疫苗接种前后角膜形貌和镜面显微镜参数。方法：对64例患者128只眼进行前瞻性评价。接种前后检查时间间隔近2个半月（75.6±4.5天）。地形评估采用Sirius角膜地形图（Sirius, CSO Inc, Florence, Italy），镜面显微镜采用Tomey EM-4000镜面显微镜（Tomey GmbH, Japan）。所有患者均接受了详细的眼科检查，包括最佳矫正视力评估（BCVA）、眼压测量（IOP）、生物显微镜下前节评估和眼底扩张检查。结果：与疫苗接种前（528.0(520.25-537.75)）相比，疫苗接种后角膜中央厚度增加542.0 (534.25-548.0)（p = 0.001）。接种前内皮细胞密度（ECD）为2597(2550.0 ~ 2646.50)，接种后至少2个月内皮细胞密度为2378.0 (2299.0 ~ 2419.0)（p p p p）结论：两剂辉瑞- biontech (BNT162b2) COVID-19 mRNA疫苗后角膜内皮细胞发生短期改变。因此，内皮细胞计数低或角膜移植患者应密切监测内皮细胞。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Ophthalmic epidemiology 医学-眼科学

CiteScore

3.70

自引率

5.60%

发文量

审稿时长

6-12 weeks

期刊介绍： Ophthalmic Epidemiology is dedicated to the publication of original research into eye and vision health in the fields of epidemiology, public health and the prevention of blindness. Ophthalmic Epidemiology publishes editorials, original research reports, systematic reviews and meta-analysis articles, brief communications and letters to the editor on all subjects related to ophthalmic epidemiology. A broad range of topics is suitable, such as: evaluating the risk of ocular diseases, general and specific study designs, screening program implementation and evaluation, eye health care access, delivery and outcomes, therapeutic efficacy or effectiveness, disease prognosis and quality of life, cost-benefit analysis, biostatistical theory and risk factor analysis. We are looking to expand our engagement with reports of international interest, including those regarding problems affecting developing countries, although reports from all over the world potentially are suitable. Clinical case reports, small case series (not enough for a cohort analysis) articles and animal research reports are not appropriate for this journal.